• 1
    Watts R, Scott D. Classification and epidemiology of the vasculitides. Bailliere's Clin Rheumatol 1997; 11: 191218.
  • 2
    Chakravarty K. Vasculitis by organ system. Bailliere's Clin Rheumatol 1997; 11: 35793.
  • 3
    Valente RM, Conn DL. Polyarteritis: polyarteritis nodosa and microscopic polyangitis. In: KlippelJH, DieppePA, editors. Rheumatology. 2nd ed. London: Mosby; 1998.
  • 4
    Hoffman GS. Wegener's granulomatosis. In: KlippelJ, DieppeP, editors. Rheumatology. 2nd ed. London: Mosby; 1998.
  • 5
    Guillem LP Churg J. Chrug-Strauss syndrome. In: KlippelJ, DieppeP, editors. Rheumatology. 2nd edition. London: Mosby; 1998.
  • 6
    Koutantji M, Pearce S, Harrold E. Psychological aspects of vasculitis. Rheumatology 2000; 39: 11739.
  • 7
    Cotch MF. The socioeconomic impact of vasculitis. Curr Opin Rheumatol 2000; 12: 203.
  • 8
    Abu-Shakra M, Smythe H, Lewtas J, Badley E, Weber D, Keystone E. Outcome of polyarteritis nodosa and Churg-Strauss syndrome. Arthritis Rheum 1994; 12: 17981803.
  • 9
    Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 222030.
  • 10
    Hoffman GS, Drucker Y, Cotch MF, Locker GA, Easley K, Kwoh K. Wegener's granulomatosis (WG): patient-reported effects of disease on health, function and income. Arthritis Rheum 1998; 41: 225762.
  • 11
    Boomsma MM, Stegeman CA, Cohen Tervaert JW. Comparison of Dutch and US patients' perceptions of the effects of Wegener's granulomatosis on health, function, income and interpersonal relationships: comment on the article by Hoffman et al. Arthritis Rheum 1999; 42: 24956.
  • 12
    Exley AR, Moots RM, Carruthers D, Bacon P. Short-form-36 in vasculitis. Clin Exp Immunol 1995; 63 Suppl 1: 101.
  • 13
    Herlyn K, Reinhold-Keller E, Zeidler A, Raspe H, Gutfleisch J, Peter HH, et al. Health-related quality of life in primary systemic vasculitides. Arthritis Rheum 1998; 41 Suppl 9: S122.
  • 14
    Raza K, Wilson A, Carruthers DM, Reay C, Amft N, Bacon PA. Impaired SF36 in patients with primary systemic necrotizing vascultis (1oSNV): influence on factors besides disease activity and damage. Arthritis Rheum 1999; 42 Suppl 9: S315.
  • 15
    Grove ML, Wilson A, Raza K, Carruthers DM, Bacon PA. Patients with damage from primary systemic vasculitis experience impaired physical health as measured by the SF36. Rheumatology 2001; 40 Suppl: 125.
  • 16
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 17
    Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 11017.
  • 18
    Jennette J, Falk R, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vaculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 18792.
  • 19
    Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094100.
  • 20
    Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotising vasculitis. QJM 1994; 87: 6718.
  • 21
    Exley AR, Bacon PA, Luqmani R, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the vasculitis damage index (VDI) for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 37180.
  • 22
    Herrmann C. International experiences with the hospital anxiety and depression scale: a review of validation data and clinical results. J Psychosom Res 1997; 42: 1741.
  • 23
    Jenkinson C, Wright L, Coulter A. Quality of life measurement in health care: a review of measures and population norms for the UK SF-36. Oxford: Health Services Research Unit; 1996.
  • 24
    Fries J, Spitz P, Young D. The dimensions of health outcomes: the Health Assessment Questionnaire disability and pain scales. J Rheumatol 1982; 9: 78993.
  • 25
    Fransen J, Stucki G. Current use of health status instruments in randomised controlled trials on patients with rheumatoid arthritis. Dis Manage Health Outcomes 1998; 3: 2717.
  • 26
    Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986; 27: 11726.
  • 27
    Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: TurkCD, MelzackR, editors. Handbook of pain assessment. London: The Guildford Press; 1992. p. 13551.
  • 28
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 29
    Bowling A. Measuring disease. Philadelphia: Open University Press; 1995.
  • 30
    Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999; 14: 124.
  • 31
    Moorey S, Greer S, Watson M, Gorman C, Rowden L, Tunmore R, et al. The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychiatry 1991; 158: 2559.
  • 32
    Burckhardt C, Archenholtz B, Mannerkorpi K, Bjelle A. Quality of life of Swedish women with fibromyalgia syndrome, rheumatoid arthritis or systemic lupus erythematosus. J Musculoskel Pain 1993; 1: 199207.
  • 33
    Drent M, Wirnsberger R, Breteler M, Kock L, Vries J, Wouters E. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 5966.